US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns
US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...
HKG: 2269
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China,...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall
WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...